4.7 Article

Validation of a Novel Method for Determining the Renal Threshold for Glucose Excretion in Untreated and Canagliflozin-treated Subjects With Type 2 Diabetes Mellitus

Journal

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Volume 98, Issue 5, Pages E867-E871

Publisher

ENDOCRINE SOC
DOI: 10.1210/jc.2012-4205

Keywords

-

Funding

  1. Janssen Research & Development, LLC
  2. Janssen Global Services, LLC
  3. Astellas Pharma
  4. Bayer Health Care
  5. Becton
  6. Dickinson and Company
  7. Biocon
  8. Boehringer Ingelheim
  9. Eli Lilly and Company
  10. Evolva
  11. Hoffmann LaRoche
  12. Johnson Johnson
  13. Lundbeck
  14. Novo Nordisk
  15. Noxxon
  16. OSI Prosidion
  17. Sanofi-Aventis
  18. Sirtris
  19. Skye Pharma

Ask authors/readers for more resources

Context: The stepwise hyperglycemic clamp procedure(SHCP) is the gold standard for measuring the renal threshold for glucose excretion (RTG), but its use is limited to small studies in specialized laboratories. Objective: The objective of the study was to validate a new method for determining RTG using data obtained during a mixed-meal tolerance test (MMTT) in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus (T2DM). Design: This was an open-label study with 2 sequential parts. Setting: The study was performed at a single center in Germany. Patients: Twenty-eight subjects with T2DM were studied. Interventions: No treatment intervention was given in part 1. In part 2, subjects were treated with canagliflozin 100 mg/d for 8 days. In each part, subjects underwent an MMTT and a 5-step SHCP on consecutive days. Main Outcome Measures: For both methods, RTG was estimated using measured blood glucose (BG) and urinary glucose excretion (UGE); estimated glomerular filtration rates were also used to determine RTG during the MMTT. The methods were compared using the concordance correlation coefficient and geometric mean ratios. Results: In untreated and canagliflozin-treated subjects, the relationship between UGE rate and BG was well described by a threshold relationship. Good agreement was obtained between the MMTT-based and SHCP-derived RTG values. The concordance correlation coefficient (for all subjects) was 0.94; geometric mean ratios (90% confidence intervals) for RTG values (MMTT/SHCP) were 0.93 (0.89-0.96) in untreated subjects and 1.03 (0.78-1.37) in canagliflozin-treated subjects. Study procedures and treatments were generally well tolerated in untreated and canagliflozin-treated subjects. Conclusions: In both untreated and canagliflozin-treated subjects with T2DM, RTG can be accurately estimated from measured BG, UGE, and estimated glomerular filtration rates using an MMTT-based method.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available